What should you pay attention to when taking Nilotinib Hydrochloride Tablets?

Before starting to use nilotinib hydrochloride tablets, patients should inform their doctors in detail about their health conditions, including whether they have other diseases and other drugs they are taking, to avoid potential drug interactions.

For patients with advanced or metastatic NSCLC (non-small cell lung cancer), evaluation for EGFR (epidermal growth factor receptor) mutations is recommended before taking nilotinib. This step is critical because it helps determine whether a patient is a candidate for nilotinib treatment and predicts treatment efficacy.

For patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia chronic phase(Ph+ CML-CP), 300 mgorally twice daily. For resistant or intolerantPh+ CML-CP and accelerated phase chronic myeloid leukemia (CML-AP) patients, 400 mgorally twice daily.

Since nilotinib may cause prolongation of the electrocardiogramQT interval, electrocardiogram examinations should be performed regularly during treatment. If QTc exceeds a specific number of milliseconds, medication should be suspended and timely communication should be communicated to the doctor. Nilotinib may cause hematological toxicity, so patients need regular blood tests to detect and deal with any abnormalities promptly.

While taking nilotinib, patients may experience a variety of adverse reactions, such as nausea, vomiting, diarrhea, rash, etc. Most of these reactions are mild to moderate, but if symptoms are severe or persist, you should seek medical attention promptly. Nilotinib may also cause some serious adverse reactions, such as abnormal liver function and electrolyte imbalance. Therefore, patients should pay close attention to their physical condition during medication and seek medical attention immediately if any abnormalities occur.

If patients need to take other drugs at the same time while taking nilotinib, they should consult their doctor in advance to avoid drug-drug interactions that may affect efficacy or increase the risk of adverse reactions.